Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.

8128 Background: Renal impairment (RI) affects >50% of patients (pts) with multiple myeloma (MM). It confers shorter survival and prevents adequate dosing by exacerbating drug side effects. Carfilz...